APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Vulvovaginal Candidiasis

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.

Selected research

Market Outlook & Growth Opportunities

Global Drugs for Vulvovaginal Candidiasis Market Outlook and Growth Opportunities 2026

Report ID 173986600425 December 2025190 pages

Choose your research edition.

Industry ResearchDrugs for Vulvovaginal Candidiasis Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Vulvovaginal Candidiasis Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Drugs for Vulvovaginal Candidiasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Vulvovaginal Candidiasis Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Vulvovaginal Candidiasis Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.

The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.

Read the full market overview

The Asia-Pacific region is the world's largest market, with a market share of about 45%, followed by North America with nearly 20%

This report provides an overview of the global Drugs for Vulvovaginal Candidiasis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Vulvovaginal Candidiasis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Vulvovaginal Candidiasis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for Vulvovaginal Candidiasis market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs for Vulvovaginal Candidiasis Segment by Company

Bayer

Perrigo

J & J

Pfizer

Bristol-Myers Squibb

Effik

Teva

Sanofi

Cisen Pharmaceutical

Kingyork Group

Drugs for Vulvovaginal Candidiasis Segment by Type

Cream

Pessary

Other

Drugs for Vulvovaginal Candidiasis Segment by Application

Hospital & Clinic

Pharmacy

Drugs for Vulvovaginal Candidiasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs for Vulvovaginal Candidiasis status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Drugs for Vulvovaginal Candidiasis market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for Vulvovaginal Candidiasis significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for Vulvovaginal Candidiasis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Vulvovaginal Candidiasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Vulvovaginal Candidiasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Vulvovaginal Candidiasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs for Vulvovaginal Candidiasis market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Vulvovaginal Candidiasis industry.

Chapter 3: Detailed analysis of Drugs for Vulvovaginal Candidiasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Drugs for Vulvovaginal Candidiasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Drugs for Vulvovaginal Candidiasis in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for Vulvovaginal Candidiasis Industry Trends Table 2. Drugs for Vulvovaginal Candidiasis Industry Drivers Table 3. Drugs for Vulvovaginal Candidiasis Industry Opportunities and Challenges Table 4. Drugs for Vulvovaginal Candidiasis Industry Restraints Table 5. Global Drugs for Vulvovaginal Candidiasis Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Company (2021-2026) Table 7. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Drugs for Vulvovaginal Candidiasis Sales Volume Share by Company (2021-2026) Table 9. Global Drugs for Vulvovaginal Candidiasis Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Drugs for Vulvovaginal Candidiasis Company Ranking, (2024-2026) & (USD Million) Table 11. Global Drugs for Vulvovaginal Candidiasis Key Company Manufacturing Base & Headquarters Table 12. Global Drugs for Vulvovaginal Candidiasis Company, Product Type & Application Table 13. Global Drugs for Vulvovaginal Candidiasis Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs for Vulvovaginal Candidiasis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Cream Table 18. Significant Companies of Pessary Table 19. Significant Companies of Other Table 20. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Drugs for Vulvovaginal Candidiasis Sales Volume Share by Type (2021-2026) Table 24. Global Drugs for Vulvovaginal Candidiasis Sales Volume Share by Type (2027-2032) Table 25. Global Drugs for Vulvovaginal Candidiasis Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Drugs for Vulvovaginal Candidiasis Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Drugs for Vulvovaginal Candidiasis Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Drugs for Vulvovaginal Candidiasis Sales Value Share by Type (2021-2026) Table 29. Global Drugs for Vulvovaginal Candidiasis Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital & Clinic Table 31. Significant Companies of Pharmacy Table 32. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Drugs for Vulvovaginal Candidiasis Sales Volume Share by Application (2021-2026) Table 36. Global Drugs for Vulvovaginal Candidiasis Sales Volume Share by Application (2027-2032) Table 37. Global Drugs for Vulvovaginal Candidiasis Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Drugs for Vulvovaginal Candidiasis Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Drugs for Vulvovaginal Candidiasis Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Drugs for Vulvovaginal Candidiasis Sales Value Share by Application (2021-2026) Table 41. Global Drugs for Vulvovaginal Candidiasis Sales Value Share by Application (2027-2032) Table 42. Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Drugs for Vulvovaginal Candidiasis Sales by Region (2021-2026) & (K Units) Table 44. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2021-2026) Table 45. Global Drugs for Vulvovaginal Candidiasis Sales by Region (2027-2032) & (K Units) Table 46. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2027-2032) Table 47. Global Drugs for Vulvovaginal Candidiasis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Drugs for Vulvovaginal Candidiasis Sales Value Share by Region (2021-2026) Table 50. Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Drugs for Vulvovaginal Candidiasis Sales Value Share by Region (2027-2032) Table 52. Global Drugs for Vulvovaginal Candidiasis Market Average Price (USD/Unit) by Region (2021-2026) Table 53. Global Drugs for Vulvovaginal Candidiasis Market Average Price (USD/Unit) by Region (2027-2032) Table 54. Global Drugs for Vulvovaginal Candidiasis Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Drugs for Vulvovaginal Candidiasis Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Drugs for Vulvovaginal Candidiasis Sales by Country (2021-2026) & (K Units) Table 57. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2021-2026) Table 58. Global Drugs for Vulvovaginal Candidiasis Sales by Country (2027-2032) & (K Units) Table 59. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2027-2032) Table 60. Global Drugs for Vulvovaginal Candidiasis Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Drugs for Vulvovaginal Candidiasis Sales Value Market Share by Country (2021-2026) Table 62. Global Drugs for Vulvovaginal Candidiasis Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Drugs for Vulvovaginal Candidiasis Sales Value Market Share by Country (2027-2032) Table 64. Bayer Company Information Table 65. Bayer Business Overview Table 66. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 67. Bayer Drugs for Vulvovaginal Candidiasis Product Portfolio Table 68. Bayer Recent Development Table 69. Perrigo Company Information Table 70. Perrigo Business Overview Table 71. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 72. Perrigo Drugs for Vulvovaginal Candidiasis Product Portfolio Table 73. Perrigo Recent Development Table 74. J & J Company Information Table 75. J & J Business Overview Table 76. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 77. J & J Drugs for Vulvovaginal Candidiasis Product Portfolio Table 78. J & J Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 82. Pfizer Drugs for Vulvovaginal Candidiasis Product Portfolio Table 83. Pfizer Recent Development Table 84. Bristol-Myers Squibb Company Information Table 85. Bristol-Myers Squibb Business Overview Table 86. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 87. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Portfolio Table 88. Bristol-Myers Squibb Recent Development Table 89. Effik Company Information Table 90. Effik Business Overview Table 91. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 92. Effik Drugs for Vulvovaginal Candidiasis Product Portfolio Table 93. Effik Recent Development Table 94. Teva Company Information Table 95. Teva Business Overview Table 96. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 97. Teva Drugs for Vulvovaginal Candidiasis Product Portfolio Table 98. Teva Recent Development Table 99. Sanofi Company Information Table 100. Sanofi Business Overview Table 101. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 102. Sanofi Drugs for Vulvovaginal Candidiasis Product Portfolio Table 103. Sanofi Recent Development Table 104. Cisen Pharmaceutical Company Information Table 105. Cisen Pharmaceutical Business Overview Table 106. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 107. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Portfolio Table 108. Cisen Pharmaceutical Recent Development Table 109. Kingyork Group Company Information Table 110. Kingyork Group Business Overview Table 111. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 112. Kingyork Group Drugs for Vulvovaginal Candidiasis Product Portfolio Table 113. Kingyork Group Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Drugs for Vulvovaginal Candidiasis Distributors List Table 117. Drugs for Vulvovaginal Candidiasis Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Drugs for Vulvovaginal Candidiasis Product Image Figure 2. Global Drugs for Vulvovaginal Candidiasis Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Vulvovaginal Candidiasis Sales Value (2021-2032) & (US$ Million) Figure 4. Global Drugs for Vulvovaginal Candidiasis Sales (2021-2032) & (K Units) Figure 5. Global Drugs for Vulvovaginal Candidiasis Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Drugs for Vulvovaginal Candidiasis Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Cream Image Figure 10. Pessary Image Figure 11. Other Image Figure 12. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Drugs for Vulvovaginal Candidiasis Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Drugs for Vulvovaginal Candidiasis Sales Volume Share by Type (2021-2032) Figure 15. Global Drugs for Vulvovaginal Candidiasis Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Drugs for Vulvovaginal Candidiasis Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Drugs for Vulvovaginal Candidiasis Sales Value Share by Type (2021-2032) Figure 18. Hospital & Clinic Image Figure 19. Pharmacy Image Figure 20. Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Drugs for Vulvovaginal Candidiasis Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Drugs for Vulvovaginal Candidiasis Sales Volume Share by Application (2021-2032) Figure 23. Global Drugs for Vulvovaginal Candidiasis Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Drugs for Vulvovaginal Candidiasis Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Drugs for Vulvovaginal Candidiasis Sales Value Share by Application (2021-2032) Figure 26. Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Drugs for Vulvovaginal Candidiasis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Drugs for Vulvovaginal Candidiasis Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Drugs for Vulvovaginal Candidiasis Sales Value (2021-2032) & (US$ Million) Figure 31. North America Drugs for Vulvovaginal Candidiasis Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Drugs for Vulvovaginal Candidiasis Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Drugs for Vulvovaginal Candidiasis Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Drugs for Vulvovaginal Candidiasis Sales Value (2021-2032) & (US$ Million) Figure 37. South America Drugs for Vulvovaginal Candidiasis Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Drugs for Vulvovaginal Candidiasis Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Drugs for Vulvovaginal Candidiasis Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Cream
  • Pessary
  • Other
Applications
  • Hospital & Clinic
  • Pharmacy
Companies covered
  • Bayer
  • Perrigo
  • J & J
  • Pfizer
  • Bristol-Myers Squibb
  • Effik
  • Teva
  • Sanofi
  • Cisen Pharmaceutical
  • Kingyork Group

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Value (2021-2032)
  4. 1.2.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume (2021-2032)
  5. 1.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Drugs for Vulvovaginal Candidiasis Market Dynamics
  1. 2.1 Drugs for Vulvovaginal Candidiasis Industry Trends
  2. 2.2 Drugs for Vulvovaginal Candidiasis Industry Drivers
  3. 2.3 Drugs for Vulvovaginal Candidiasis Industry Opportunities and Challenges
  4. 2.4 Drugs for Vulvovaginal Candidiasis Industry Restraints
3 Drugs for Vulvovaginal Candidiasis Market by Company
  1. 3.1 Global Drugs for Vulvovaginal Candidiasis Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Company (2021-2026)
  4. 3.4 Global Drugs for Vulvovaginal Candidiasis Average Price by Company (2021-2026)
  5. 3.5 Global Drugs for Vulvovaginal Candidiasis Company Ranking (2024-2026)
  6. 3.6 Global Drugs for Vulvovaginal Candidiasis Company Manufacturing Base and Headquarters
  7. 3.7 Global Drugs for Vulvovaginal Candidiasis Company Product Type and Application
  8. 3.8 Global Drugs for Vulvovaginal Candidiasis Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Drugs for Vulvovaginal Candidiasis Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Drugs for Vulvovaginal Candidiasis Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Drugs for Vulvovaginal Candidiasis Market by Type
  1. 4.1 Drugs for Vulvovaginal Candidiasis Type Introduction
  2. 4.1.1 Cream
  3. 4.1.2 Pessary
  4. 4.1.3 Other
  5. 4.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type
  6. 4.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Drugs for Vulvovaginal Candidiasis Sales Value by Type
  10. 4.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Drugs for Vulvovaginal Candidiasis Sales Value by Type (2021-2032)
  12. 4.3.3 Global Drugs for Vulvovaginal Candidiasis Sales Value Share by Type (2021-2032)
5 Drugs for Vulvovaginal Candidiasis Market by Application
  1. 5.1 Drugs for Vulvovaginal Candidiasis Application Introduction
  2. 5.1.1 Hospital & Clinic
  3. 5.1.2 Pharmacy
  4. 5.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application
  5. 5.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Drugs for Vulvovaginal Candidiasis Sales Value by Application
  9. 5.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Drugs for Vulvovaginal Candidiasis Sales Value by Application (2021-2032)
  11. 5.3.3 Global Drugs for Vulvovaginal Candidiasis Sales Value Share by Application (2021-2032)
6 Drugs for Vulvovaginal Candidiasis Regional Sales and Value Analysis
  1. 6.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Vulvovaginal Candidiasis Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2021-2026
  4. 6.2.2 Global Drugs for Vulvovaginal Candidiasis Sales by Region (2027-2032)
  5. 6.3 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (2021-2032)
  7. 6.4.1 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region: 2021-2026
  8. 6.4.2 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (2027-2032)
  9. 6.5 Global Drugs for Vulvovaginal Candidiasis Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Drugs for Vulvovaginal Candidiasis Sales Value (2021-2032)
  12. 6.6.2 North America Drugs for Vulvovaginal Candidiasis Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Drugs for Vulvovaginal Candidiasis Sales Value (2021-2032)
  15. 6.7.2 Europe Drugs for Vulvovaginal Candidiasis Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Drugs for Vulvovaginal Candidiasis Sales Value (2021-2032)
  21. 6.9.2 South America Drugs for Vulvovaginal Candidiasis Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Value Share by Country, 2025 VS 2032
7 Drugs for Vulvovaginal Candidiasis Country-level Sales and Value Analysis
  1. 7.1 Global Drugs for Vulvovaginal Candidiasis Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for Vulvovaginal Candidiasis Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Drugs for Vulvovaginal Candidiasis Sales by Country (2021-2032)
  4. 7.3.1 Global Drugs for Vulvovaginal Candidiasis Sales by Country (2021-2026)
  5. 7.3.2 Global Drugs for Vulvovaginal Candidiasis Sales by Country (2027-2032)
  6. 7.4 Global Drugs for Vulvovaginal Candidiasis Sales Value by Country (2021-2032)
  7. 7.4.1 Global Drugs for Vulvovaginal Candidiasis Sales Value by Country (2021-2026)
  8. 7.4.2 Global Drugs for Vulvovaginal Candidiasis Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Drugs for Vulvovaginal Candidiasis Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Drugs for Vulvovaginal Candidiasis Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Drugs for Vulvovaginal Candidiasis Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bayer
  2. 8.1.1 Bayer Company Information
  3. 8.1.2 Bayer Business Overview
  4. 8.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bayer Drugs for Vulvovaginal Candidiasis Product Portfolio
  6. 8.1.5 Bayer Recent Developments
  7. 8.2 Perrigo
  8. 8.2.1 Perrigo Company Information
  9. 8.2.2 Perrigo Business Overview
  10. 8.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Product Portfolio
  12. 8.2.5 Perrigo Recent Developments
  13. 8.3 J & J
  14. 8.3.1 J & J Company Information
  15. 8.3.2 J & J Business Overview
  16. 8.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 J & J Drugs for Vulvovaginal Candidiasis Product Portfolio
  18. 8.3.5 J & J Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Bristol-Myers Squibb
  26. 8.5.1 Bristol-Myers Squibb Company Information
  27. 8.5.2 Bristol-Myers Squibb Business Overview
  28. 8.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Portfolio
  30. 8.5.5 Bristol-Myers Squibb Recent Developments
  31. 8.6 Effik
  32. 8.6.1 Effik Company Information
  33. 8.6.2 Effik Business Overview
  34. 8.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Effik Drugs for Vulvovaginal Candidiasis Product Portfolio
  36. 8.6.5 Effik Recent Developments
  37. 8.7 Teva
  38. 8.7.1 Teva Company Information
  39. 8.7.2 Teva Business Overview
  40. 8.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Teva Drugs for Vulvovaginal Candidiasis Product Portfolio
  42. 8.7.5 Teva Recent Developments
  43. 8.8 Sanofi
  44. 8.8.1 Sanofi Company Information
  45. 8.8.2 Sanofi Business Overview
  46. 8.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Product Portfolio
  48. 8.8.5 Sanofi Recent Developments
  49. 8.9 Cisen Pharmaceutical
  50. 8.9.1 Cisen Pharmaceutical Company Information
  51. 8.9.2 Cisen Pharmaceutical Business Overview
  52. 8.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Portfolio
  54. 8.9.5 Cisen Pharmaceutical Recent Developments
  55. 8.10 Kingyork Group
  56. 8.10.1 Kingyork Group Company Information
  57. 8.10.2 Kingyork Group Business Overview
  58. 8.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Portfolio
  60. 8.10.5 Kingyork Group Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs for Vulvovaginal Candidiasis Value Chain Analysis
  2. 9.1.1 Drugs for Vulvovaginal Candidiasis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs for Vulvovaginal Candidiasis Sales Mode & Process
  6. 9.2 Drugs for Vulvovaginal Candidiasis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs for Vulvovaginal Candidiasis Distributors
  9. 9.2.3 Drugs for Vulvovaginal Candidiasis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst